Interleukin-2 inhalation - Immunservice
Latest Information Update: 26 Feb 2016
At a glance
- Originator Immunservice
- Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cancer metastases
Most Recent Events
- 26 Feb 2016 Interleukin-2 inhalation - Immunservice receives Orphan Drug status for Cancer metastases in European Union